Project Grant R03CA300834
Award Date
6/20/25
Completion Date
5/31/27
Dollars Obligated
$159K
Federal Agency
National Cancer Institute
Awardee
Emory University (S352L5PJLMP8)
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Georgia, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $613,827 to Mayo Clinic Arizona to conduct research on improving radiation therapy delivery models and minimizing adverse events in spot scanning proton therapy. The key products and services to be delivered include: Developing a novel "Dose-LET Volume Histogram" tool to visualize and analyze the relationship between radiation dose, linear energy transfer (LET), and...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $602,361 to Yale University to develop deep learning-based models for personalized treatment planning of Prostate-Specific Membrane Antigen (PSMA) Radioligand Therapy (RPT) for metastatic castration-resistant prostate cancer. The project aims to leverage imaging data from pre-treatment PSMA-PET scans and during-treatment SPECT scans to build predictive models that can estimate...
This federal Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), provides $695,814 to Mayo Clinic Arizona to develop AI-powered technologies that enable online adaptive proton therapy for head and neck cancer treatment. The key products and services to be delivered include: An asymmetric autoencoder network with vision-transformer...
This Project Grant award from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) provides $538,553.00 to the University of Miami to conduct longitudinal imaging and liquid biopsy studies to identify markers for prostate cancer radiotherapy outcomes. The goal is to develop a multivariable model that incorporates pre-treatment and longitudinal multiparametric MRI features and circulating tumor cells to guide physicians' decisions on radiation therapy...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $435,773 to the University of Maryland, Baltimore to develop an engineered prodrug treatment for inhibiting cancer growth and metastasis, particularly for ovarian, lung, and colon cancers. The research aims to leverage tumor-associated hyperactive membrane-anchored serine proteases on the surface of malignant tumor cells to selectively deliver potent cytotoxins and enhance sensitivity...
The National Cancer Institute (NCI) awarded a $399,214 Project Grant under CFDA 93.395 - Cancer Treatment Research to Proton Bio, Inc., a minority-owned business located in Baltimore, Maryland. The grant supports a 12-month project to develop and evaluate a novel therapy targeting the proton-sensing receptor GPR68 as a potential treatment for glioblastoma (GBM), the most common and aggressive form of adult brain cancer. The project will focus on three key objectives: 1) define the in vitro...
This federal Cooperative Agreement award of $641,155 from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) aims to develop a robust protoacoustic dosimeter for 3D in vivo dosimetry in proton flash therapy. The project, led by the University of California, Irvine, in partnership with the University of Maryland, Baltimore and the University of Oklahoma Health Sciences Center, will create a novel protoacoustic/ultrasound dual-modality imaging system (PUDIS) to enable precise...
This federal Project Grant award of $644,622 from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) aims to enhance radioligand therapy for prostate cancer through the development of biomarker and dosimetry-guided personalized treatment approaches. The key objectives are to: 1) develop a novel method for bone marrow dosimetry using macro/micro Monte Carlo modeling, 2) build predictive models to estimate absorbed radiation doses from pre-therapy PET...
This Project Grant award of $577,818 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to develop new effective therapeutic combinations to boost the "abscopal effect" and improve clinical outcomes for patients with advanced cancers treated with radiotherapy. The funded research project will: 1) Dissect the mechanisms by which the immune checkpoint molecule B7-H3 impairs CD8 T cell cytotoxicity, using proximity labeling technologies and mouse models, and...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $662,516 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to conduct research on improving drug delivery for chemoradiotherapy in locally advanced head and neck squamous cell carcinoma and anaplastic thyroid cancer. The project aims to evaluate how fractionated radiation affects the tumor microenvironment to influence passive drug delivery, and test...